Market capitalization | AUD8.35b |
Enterprise Value | AUD8.25b |
P/E (TTM) P/E ratio | 165.45 |
EV/FCF (TTM) EV/FCF | 241.58 |
EV/Sales (TTM) EV/Sales | 12.78 |
P/S ratio (TTM) P/S ratio | 12.93 |
P/B ratio (TTM) P/B ratio | 20.64 |
Revenue growth (TTM) Revenue growth | 80.92% |
Revenue (TTM) Revenue | AUD645.68m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
8 Analysts have issued a Telix Pharmaceuticals forecast:
8 Analysts have issued a Telix Pharmaceuticals forecast:
Jun '24 |
+/-
%
|
||
Revenue | 646 646 |
81%
81%
|
|
Gross Profit | 463 463 |
241%
241%
|
|
EBITDA | 72 72 |
161%
161%
|
EBIT (Operating Income) EBIT | 65 65 |
198%
198%
|
Net Profit | 49 49 |
204%
204%
|
In millions AUD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.
Head office | Australia |
CEO | Christian Behrenbruch |
Founded | 2017 |
Website | www.telixpharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.